Bernstein analyst Florent Cespedes maintained a Buy rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £22.90.

Millie, a modern maternity clinic, secured $12 million in Series A funding led by existing investors RH Capital, TMV, ...

US regulators have approved a new meningitis vaccine developed by GSK, sparking cautious optimism for the sector in the wake of Donald Trump's election for a second term as President. The Food ...

GSK has reached an agreement that it says will resolve 93% of the outstanding lawsuits brought against the company claiming that its gastrointestinal drug Zantac caused cancer. The company has ...

Commenting on the results, Bhushan Akshikar, MD of GlaxoSmithKline Pharmaceuticals, highlighted the company’s strategic initiatives in strengthening its market presence and enhancing access to ...

GSK has claimed its second breakthrough designation from the FDA for antibody-drug conjugate GSK5764227, which it licensed from China's Hansoh Pharma in a $1.7 billion deal. The status has been ...

In short, the GSK share price has disappointed shareholders for years. I know, as I have a tiny holding in this business, while my wife has a more meaningful stake. For decades, GSK was my family ...

Involves transaction of at least 0.5% of the listed shares of a company. What was Glaxosmithkline Pharmaceuticals Ltd share price previously? Glaxosmithkline Pharmaceuticals Ltd share price was up ...

A team can win a game but fail to cover the spread if they don’t win by enough points. A push happens if the outcome of the game is the same amount as the spread; in this case, bets are returned.

Teva Pharmaceutical Industries Ltd. ADR-0.93% $19.32B ...